Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface

a dimer and inhibitor technology, applied in the field of molecular biology, biochemistry and cell biology of the epidermal growth factor receptor (egfr), can solve the problems of ineffective pharmaceuticals for many egfr-related illnesses, inefficient process for most drug discovery uses, and interference of egfr kinase activity of these proteins

Inactive Publication Date: 2010-05-13
RGT UNIV OF CALIFORNIA
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]In another aspect, the invention provides a method of targeted drug discovery which includes the following steps: (a) determining structural information of an EGFR kinase domain co-crystallized with a control molecule; (b) identifying residues of the EGFR kinase domain which interact with said the molecule; (c) comparing information from (a) and (b) to a database of potential therapeutics; and (d) selecting potential therapeutics from the database that are most likely to interact with the EGFR

Problems solved by technology

Studies have shown that mutations in the catalytic domain of EGFR can interfere with the kinase activity of these proteins.
However, the high rate of false negatives inherent to a yeast two hybrid screen makes such a process inefficient for most drug discovery uses.
Drugs targeting EGFR that are currently in use inhibit EGFR through interaction with the active site, but such pharmaceuticals are not effective for many EGFR-related illnesses.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
  • Novel inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
  • Novel inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface

Examples

Experimental program
Comparison scheme
Effect test

example 1

Expression and Purification of the Kinase Domain

[0218]DNA encoding residues 672-998 of human EGFR was cloned into pFAST BAC HT (Invitrogen) using the NcoI and HindIII restriction sites (FIG. 2). The construct contains an N-terminal 6-His tag, a linker, and a cleavage site for the Tobacco Etch Virus protease (TEV). (MSYHHHHHHDYDIPTTENLYFQGAM). All mutations were introduced using the Quik-change site-directed mutagenesis kit (Stratagene). Sequences of all plasmids were confirmed by DNA sequencing.

[0219]Recombinant bacmid (Bac-to-Bac expression system, Gihco BRL) were transfected into Sf9 cells grown in suspension. Cells were harvested 2-3 days after infection by centrifugation at 4000×g and resuspended in a buffer containing 50 mM Tris, 5% glycerol. 1 mM DTT, and protease inhibitor cocktail (Roche), pH 8.0.

[0220]Cells were homogenized by French press in resuspension buffer and the lysate was centrifuged at 40000×g for 45 minutes. The supernatant was then loaded onto a 60 ml Q-Sepharos...

example ii

Preparation of Small Unilamellar Vesicles

[0222]DOPC and DOGS-NTA-Ni lipids in chloroform (Avanti Polar Lipids, Inc) were mixed in a glass tube. A lipid film was formed upon removing chloroform under a stream of argon gas, followed by putting the tube under vacuum for at least 3 hours.

[0223]Rehydration buffer (10 mM MgCl2, 20 mM Tris, pH 7.5) was added to the lipid film and incubated for at least three hours. Intermittent vigorous vortexing during the incubation was applied to convert the lipid film into large, multilamellar vesicles.

[0224]The multilamellar vesicles were then forced through a polycarbonate filter (pore size: 100 nm) 21-41 times using a mini extruder (Avanti Polar Lipids, Inc) to yield homogenous small unilamellar vesicles.

[0225]The diameter of the vesicles was measured by static light scatting to be in a range from 100-200 nm. (FIG. 16).

example iii

Kinase Assay in Solution and with Vesicles

[0226]A continuous enzyme-coupled kinase assay was performed to measure the kinase activity of the proteins as described in Barker et al., ((1995) Biochemistry, Vol. 34(54): 14843-51), with modifications, as described herein. The ATP concentration was kept to 0.5 mM.

[0227]The buffer used contained 10 mM. MgCl2, 20 mM Tris, and pH 7.5. Replacement of MgCl2 by MnCl2 in the assays resulted in a substantial increase of the catalytic activity of the kinase domain, as noted previously (Mohammadi et al., (1993) Biochemistry (34):8742-8.; Wedergaertner and Gill, (1989) Journal of Biological Chemistry 264(19):11346-53). The substrate peptide was derived from the region spanning Y1173 in EGFR (TAENAEYLRVAPQ). All proteins used in this assay contained the N-terminal (is)6 tag unless otherwise noted.

[0228]The protein concentrations of the EGFR kinase domain used in the assay ranged from 3.5 to 14 μM. The total concentration of the DOGS-NTA-Ni in the bul...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Catalytic activityaaaaaaaaaa
Login to View More

Abstract

The invention provides methods and compositions for the modulation of EGFR activity, in particular, inhibition of EGFR activation through an allosteric mechanism is discloses, as is a method for targeted drug discovery and design based on models of the three dimensional structure of the kinase domains of the protein dimers.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]The present application claims the benefit of the filing dates of U.S. Provisional Patent Application No. 60 / 851,668, filed Oct. 13, 2006, and of U.S. Provisional Patent Application No. 60 / 851,921, filed Oct. 13, 2006, which are both incorporated by reference in their entirety for all purposes.FIELD OF THE INVENTION[0002]The invention relates generally to the field of molecular biology, biochemistry, and cell biology of the Epidermal Growth Factor Receptor (EGFR). In particular, the instant invention provides methods and compositions for the modulation of EGFR. EGFR receptors play critical roles in regulating cell proliferation, differentiation, and migration, and their abnormal activation is associated with a variety of human cancers, including lung, breast, pancreatic, ovarian and prostate cancer. Compositions and methods of the invention can be used to prevent, cure, treat, or ameliorate these cancers as well as other diseases associat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17C07K7/08C07K14/435C12N9/99G01N33/573A61K38/10
CPCA61K38/00C07K14/4703G01N2500/00G01N33/74C12Q1/045
Inventor KURIYAN, JOHNZHANG, XUEWUCOLE, PHILIP
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com